Business
Outset Medical Announces Pricing of Primary and Upsized Secondary Public Offering
SAN JOSE, Calif.--(BUSINESS WIRE)-- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to
About this update from Outset Medical, Inc.
[{"type":"text","content":" SAN JOSE, Calif.--(BUSINESS WIRE)--\nOutset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced today the pricing of an underwritten public offering of 2,500,000 shares of its common stock sold by Outset and 3,444,859 shares of its common stock by certain of its stockholders at a public offering price of $53.50 per share. In addition, Outset and such selling stockholders granted the underwriters a 30-day option to purchase up to an additional 891,728 shares of its common stock at the public offering price, less the underwriting discounts and commissions. The underwriting discounts and commissions will be borne by Outset with respect to the shares it sells in the offering and by the selling stockholders with respect to the shares they sell in the offering. The offering is expected to close on April 13, 2021, subject to the satisfaction of customary closing conditions. \n\nMorgan Stanley, BofA Securities and Goldman Sachs & Co. LLC are acting as joint lead book-running managers for the offering. Stifel and Cowen are acting as co-managers for the offering.\n\nA registration statement on Form S-1 relating to the shares being sold in this offering was filed with and declared effective by the U.S. Securities and Exchange Commission.\n\nThe offering is being made only by means of a prospectus. When available, a copy of the prospectus may be obtained from Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department, or by email at [email protected]; BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at [email protected]; and Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone: 1-866-471-2526, or via email: [email protected].\n\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdicti...